FDA Clearance Tracker · P920047-S137
Blazer II Cardiac Ablation System and Cable
Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Aug 14, 2025
Approved
Time to decision
36 days
Received Jul 9, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P920047-S137
- Device name
- Blazer II Cardiac Ablation System and Cable
- Applicant
- Boston Scientific Corp
- Applicant location
- St Paul, MN
- Received
- Jul 9, 2025
- Decided
- Aug 14, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P920047
Device type
- Device type
- Cardiac ablation percutaneous catheter (LPB)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
for a manufacturing site located at Boston Scientific de Costa Rica, S.R.L., El Coyol Alajuela, Coyol, Costa Rica (FEI: 3007695959) to perform ethylene oxide sterilization activities
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with DeliPMA supplement
P130013-S074 · Decided Jul 16, 2025 · 180 days after receipt · Panel Track
Device type: System, appendage closure, left atrial (NGV) · Cardiology
K243245 · Decided Oct 18, 2024 · 7 days after receipt
Device type: Unit, Cryosurgical, Accessories (GEH) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.